Tolerability and Efficacy of the Anti-CD47 Antibody Magrolimab Plus Azacitidine in Patients With Previously Untreated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
J. Clin. Oncol 2023 Sep 13;[EPub Ahead of Print], NG Daver, P Vyas, S Kambhampati, MM Al Malki, RA Larson, AS Asch, G Mannis, W Chai-Ho, TN Tanaka, TJ Bradley, D Jeyakumar, ES Wang, K Sweet, HM Kantarjian, G Garcia-Manero, R Komrokji, G Xing, G Ramsingh, C Renard, JF Zeidner, DA SallmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.